Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flows from operating activities:
Net loss	$ (43,773)	$ (21,398)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	504	490
Accretion of premium/discount on marketable securities	(980)	(473)
Non-cash lease expense	195	69
Amortization of debt issuance costs	8
Stock-based compensation expense	14,679	6,445
Change in fair value of contingent consideration	2,967	401
Other non-cash reconciling items	4	(1)
Change in operating assets and liabilities:
Prepaid expenses, other current assets and other assets	(3,416)	81
Accounts payable	(3,336)	4,865
Accrued compensation	(499)	(1,909)
Accrued clinical trial site costs	(2)	(998)
Operating lease liabilities	(40)	(56)
Other liabilities	937	(44)
Net cash used in operating activities	(32,752)	(12,528)
Cash flows from investing activities
Purchases of property and equipment	(5)	(11)
Purchases of marketable securities	(45,358)	(115,233)
Maturities of marketable securities	68,300	0
Net cash provided by (used in) investing activities	22,937	(115,244)
Cash flows from financing activities:
Payment of debt issuance costs	(62)
Proceeds from exercise of common stock warrants	3,011	923
Proceeds from exercise of stock options	269	15
Net cash provided by financing activities	3,218	938
Net decrease in cash and cash equivalents	(6,597)	(126,834)
Cash and cash equivalents, beginning of period	87,928	169,681
Cash and cash equivalents, end of period	81,331	42,847
Supplemental disclosure of non-cash operating and financing information
Cash paid for interest	$ 805
Purchases of property and equipment included in accounts payable		$ 8